FDA Approval of Oral Weight-Loss Pills Sparks Surge in U.S. Demand
The U.S. has seen a significant surge in demand for oral weight-loss pills following the FDA's approval of Wegovy, the first GLP-1 receptor agonist pill designed to treat obesity. Within ten weeks of its release, approximately 400,000 Americans began using the medication, with 80% being new to weight-loss injections. Eli Lilly also launched a competing pill, orforglipron, which quickly gained traction with 20,000 users. These pills, part of the GLP-1 receptor agonist family, mimic the human GLP-1 hormone to suppress appetite and reduce food cravings. The transition from injections to pills is seen as a more convenient option for many, although the weight-loss results are slightly less than those achieved with injections. 
